nr

(R)-Viloxazine Hydrochloride is the R-isomer of Viloxazine, a selective norepinephrine reuptake inhibitor (NRI) used as an antidepressant.

NR-V04 is a PROTAC degrader targeting NR4A1.

NR-11c is a selective and potent p38α PROTAC degrader. It effectively degrades p38α in various tumor cells. When administered to mice via intraperitoneal or tail vein injection, NR-11c primarily acts in the liver. It is used for cancer research.

NR-6A is a PROTAC designed to target p38.

Potent and selective p38α and p38β degrader (DC50 < 50 nM). Displays no significant degradation of p38γ, p38δ, JNK1/2 or ERK1/2. Inhibits phosphorylation of MK2 in UV-treated cancer cells and LPS-stimulated bone marrow-derived macrophages (BMDM). Exhibits similar effect to p38α gene knockout in BBL358 cells. Active in vivo.

NR-160 is an inhibitor of histone deacetylase 6 (HDAC6; IC50= 0.03 μM).1It is selective for HDAC6 over HDAC1, -2, -3, -4, and -8 (IC50s = 5.18, 2.26, 8.48, 55.4, and 14.7 μM, respectively). NR-160 is cytotoxic against a panel of seven cancer cell lines (IC50s = 22.5-51.8 μM). It enhances cytotoxicity induced by bortezomib in HL-60 cells, as well as cytotoxicity induced by epirubicin or daunorubicin in CCRF-HSB-2 T cell acute lymphoblastic leukemia cells.

NR-NO2 is a prospective therapeutic agent with targeted delivery and image-guided capability for use in antitumor studies, also demonstrating antibacterial effects [1].

NR-7h is a potent and selective degrader of p38α and p38β, exhibiting DC50 values of 24 nM for p38α in T47D cells and 27.2 nM in MB-MDA-231 cells, respectively [1].

Daraxonrasib (RMC-6236) is an orally effective and novel triple complex RAS (ON) MULTI inhibitor, which is a potent non covalent inhibitor of multiple RAS variants in GTP binding state. RMC-6236 has anti-tumor activity and can be used in research related to RAS driven tumors. With rich experience in compound synthesis, we can provide fast customized synthesis services for this product according to your research needs.

Anakinra (Raleukin) is a cytokine inactivator and interleukin 1 receptor antagonist that can be used to study secondary phagocytic lymphohistiocytosis and rheumatoid arthritis.

Linrodostat (BMS-986205) is a selective inhibitor of indoleamine 2,3-dioxygenase 1 (IDO1).

Nrf2-IN-1 is an nuclear factor-erythroid 2-related factor 2 (Nrf2) inhibitor. Nrf2-IN-1 is developed for the research of acute myeloid leukemia (AML).

Finrozole (MPV 2213ad) is a novel selective aromatase inhibitor that is partially reversible for breast development.

Enrasentan (sb-217242) is a mixed antagonist of ET(A) and ET(B) receptors that reduces blood pressure, prevents cardiac hypertrophy, and protects myocardial function.

NRX-1532 is a small molecule that acts as an enhancer of the β-catenin:β-TrCP interaction.

NRX-2663 enhances the interaction of β-catenin with the homologous E3 ligase SCFβ-TrCP and increases the binding affinity of β-catenin to β-TrCP (Kd: 54.8 nM, EC50: 22.9 nM).

NRX-103094 is a potent enhancer of the interaction between β-catenin and the homologous E3 ligase SCFβ-TrCP, increasing the affinity of pSer33/Ser37 β-catenin for β-TrCP with an EC50 of 62 nM and a Kd of 0.6 nM.

NRX-252114 (NRX252114) induces degradation of mutant β-catenin NRX-252114 is a potent enhancer of the interaction of β-catenin with the homologous E3 ligase SCFβ-TrCP, and is able to enhance the binding of pSer33/S37A β-catenin to β-TrCP with an EC50 of 6.5 nM and a Kd of 0.4 nM. Kd is 0.4 nM.

NRX-103095 is a potent enhancer of the interaction of β-catenin with the homologous E3 ligase SCFβ-TrCP and enhances the affinity of pSer33/Ser37 β-catenin for β-TrCP with an EC50 of 163 nM.

Sonrotoclax is a potent, orally active inhibitor of Bcl2, demonstrating effective cell-killing activity against a range of lymphoma and leukemia cell lines [1].

Nrf2 activator-3 is a potent Nrf2 activator with potential anti-inflammatory, antioxidant, and anti-tumor activities, suitable for studying neurological and immune-related diseases.

NRX-252262 is a potent enhancer of the interaction between β-Catenin and its cognate E3 ligase, SCFβ-TrCP, inducing mutant β-Catenin degradation (EC50: 3.8 nM).

Cinromide (trans-3-Bromo-N-ethylcinnamamide) is used as a novel anticonvulsant agent.

Enrofloxacin (BAY-Vp2674) is a veterinary antibacterial agent, used in poultry.